DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Ivosidenib |
DM8S6T7
|
Moderate |
Increased metabolism of Vinorelbine caused by Ivosidenib mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[23] |
Midostaurin |
DMI6E0R
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[24] |
Arn-509 |
DMT81LZ
|
Moderate |
Accelerated clearance of Vinorelbine due to the transporter induction by Arn-509. |
Acute myeloid leukaemia [2A60]
|
[24] |
Gilteritinib |
DMTI0ZO
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[20] |
Siltuximab |
DMGEATB
|
Moderate |
Additive immunosuppressive effects by the combination of Vinorelbine and Siltuximab. |
Anemia [3A00-3A9Z]
|
[24] |
Dronedarone |
DMA8FS5
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by Dronedarone. |
Angina pectoris [BA40]
|
[25] |
Voriconazole |
DMAOL2S
|
Major |
Decreased clearance of Vinorelbine due to the transporter inhibition by Voriconazole. |
Aspergillosis [1F20]
|
[26] |
Posaconazole |
DMUL5EW
|
Major |
Decreased metabolism of Vinorelbine caused by Posaconazole mediated inhibition of CYP450 enzyme. |
Aspergillosis [1F20]
|
[26] |
Roflumilast |
DMPGHY8
|
Moderate |
Additive immunosuppressive effects by the combination of Vinorelbine and Roflumilast. |
Asthma [CA23]
|
[24] |
Ofloxacin |
DM0VQN3
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Ofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[27] |
Ciprofloxacin XR |
DM2NLS9
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Ciprofloxacin XR. |
Bacterial infection [1A00-1C4Z]
|
[27] |
Dalfopristin |
DM4LTKV
|
Moderate |
Decreased metabolism of Vinorelbine caused by Dalfopristin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[28] |
Clarithromycin |
DM4M1SG
|
Major |
Decreased metabolism of Vinorelbine caused by Clarithromycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[26] |
Trovafloxacin |
DM6AN32
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Trovafloxacin. |
Bacterial infection [1A00-1C4Z]
|
[27] |
Sparfloxacin |
DMB4HCT
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Sparfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[27] |
Gemifloxacin |
DMHT34O
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Gemifloxacin. |
Bacterial infection [1A00-1C4Z]
|
[27] |
Norfloxacin |
DMIZ6W2
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Norfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[27] |
ABT-492 |
DMJFD2I
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by ABT-492. |
Bacterial infection [1A00-1C4Z]
|
[27] |
Levofloxacin |
DMS60RB
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Levofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[27] |
Troleandomycin |
DMUZNIG
|
Major |
Decreased clearance of Vinorelbine due to the transporter inhibition by Troleandomycin. |
Bacterial infection [1A00-1C4Z]
|
[26] |
Lomefloxacin |
DMVRH9C
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Lomefloxacin. |
Bacterial infection [1A00-1C4Z]
|
[27] |
Telithromycin |
DMZ4P3A
|
Major |
Decreased metabolism of Vinorelbine caused by Telithromycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[26] |
Erdafitinib |
DMI782S
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by Erdafitinib. |
Bladder cancer [2C94]
|
[29] |
Pexidartinib |
DMS2J0Z
|
Moderate |
Increased metabolism of Vinorelbine caused by Pexidartinib mediated induction of CYP450 enzyme. |
Bone/articular cartilage neoplasm [2F7B]
|
[30] |
Tucatinib |
DMBESUA
|
Major |
Decreased clearance of Vinorelbine due to the transporter inhibition by Tucatinib. |
Breast cancer [2C60-2C6Y]
|
[26] |
Palbociclib |
DMD7L94
|
Moderate |
Decreased metabolism of Vinorelbine caused by Palbociclib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[31] |
Grepafloxacin |
DMGLX0T
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Grepafloxacin. |
Bronchitis [CA20]
|
[27] |
Secobarbital |
DM14RF5
|
Moderate |
Increased metabolism of Vinorelbine caused by Secobarbital mediated induction of CYP450 enzyme. |
Chronic insomnia [7A00]
|
[32] |
PF-04449913 |
DMSB068
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by PF-04449913. |
Chronic myelomonocytic leukaemia [2A40]
|
[24] |
Mifepristone |
DMGZQEF
|
Moderate |
Decreased metabolism of Vinorelbine caused by Mifepristone mediated inhibition of CYP450 enzyme. |
Cushing syndrome [5A70]
|
[20] |
Ivacaftor |
DMZC1HS
|
Moderate |
Decreased metabolism of Vinorelbine caused by Ivacaftor mediated inhibition of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[33] |
MK-8228 |
DMOB58Q
|
Moderate |
Decreased metabolism of Vinorelbine caused by MK-8228 mediated inhibition of CYP450 enzyme. |
Cytomegaloviral disease [1D82]
|
[34] |
Aprepitant |
DM053KT
|
Moderate |
Decreased metabolism of Vinorelbine caused by Aprepitant mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[35] |
Nefazodone |
DM4ZS8M
|
Major |
Decreased clearance of Vinorelbine due to the transporter inhibition by Nefazodone. |
Depression [6A70-6A7Z]
|
[26] |
Griseofulvin |
DMK54YG
|
Moderate |
Increased metabolism of Vinorelbine caused by Griseofulvin mediated induction of CYP450 enzyme. |
Dermatophytosis [1F28]
|
[32] |
Oxcarbazepine |
DM5PU6O
|
Moderate |
Increased metabolism of Vinorelbine caused by Oxcarbazepine mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[36] |
Cenobamate |
DM8KLU9
|
Moderate |
Increased metabolism of Vinorelbine caused by Cenobamate mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[37] |
Stiripentol |
DMMSDOY
|
Moderate |
Decreased metabolism of Vinorelbine caused by Stiripentol mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[38] |
Fosphenytoin |
DMOX3LB
|
Moderate |
Accelerated clearance of Vinorelbine due to the transporter induction by Fosphenytoin. |
Epilepsy/seizure [8A61-8A6Z]
|
[39] |
Phenobarbital |
DMXZOCG
|
Moderate |
Increased metabolism of Vinorelbine caused by Phenobarbital mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[32] |
Carbamazepine |
DMZOLBI
|
Moderate |
Increased metabolism of Vinorelbine caused by Carbamazepine mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[32] |
Tazemetostat |
DMWP1BH
|
Moderate |
Increased metabolism of Vinorelbine caused by Tazemetostat mediated induction of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[40] |
Itraconazole |
DMCR1MV
|
Major |
Decreased clearance of Vinorelbine due to the transporter inhibition by Itraconazole. |
Fungal infection [1F29-1F2F]
|
[26] |
Miconazole |
DMPMYE8
|
Moderate |
Decreased metabolism of Vinorelbine caused by Miconazole mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[41] |
Ketoconazole |
DMPZI3Q
|
Major |
Decreased clearance of Vinorelbine due to the transporter inhibition by Ketoconazole. |
Fungal infection [1F29-1F2F]
|
[26] |
Boceprevir |
DMBSHMF
|
Major |
Decreased metabolism of Vinorelbine caused by Boceprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[26] |
Telaprevir |
DMMRV29
|
Major |
Decreased metabolism of Vinorelbine caused by Telaprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[26] |
Rifampin |
DMA8J1G
|
Moderate |
Increased metabolism of Vinorelbine caused by Rifampin mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[32] |
Rifapentine |
DMCHV4I
|
Moderate |
Increased metabolism of Vinorelbine caused by Rifapentine mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[32] |
Brentuximab vedotin |
DMWLC57
|
Moderate |
Increased risk of peripheral neuropathy by the combination of Vinorelbine and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[42] |
Delavirdine |
DM3NF5G
|
Major |
Decreased metabolism of Vinorelbine caused by Delavirdine mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[26] |
Fosamprenavir |
DM4W9B3
|
Major |
Decreased metabolism of Vinorelbine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[26] |
Cobicistat |
DM6L4H2
|
Major |
Decreased metabolism of Vinorelbine caused by Cobicistat mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[26] |
Efavirenz |
DMC0GSJ
|
Moderate |
Increased metabolism of Vinorelbine caused by Efavirenz mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[43] |
Saquinavir |
DMG814N
|
Major |
Decreased metabolism of Vinorelbine caused by Saquinavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[26] |
Etravirine |
DMGV8QU
|
Moderate |
Increased metabolism of Vinorelbine caused by Etravirine mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[44] |
Zalcitabine |
DMH7MUV
|
Moderate |
Increased risk of peripheral neuropathy by the combination of Vinorelbine and Zalcitabine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[45] |
Amprenavir |
DMLMXE0
|
Major |
Decreased metabolism of Vinorelbine caused by Amprenavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[26] |
Darunavir |
DMN3GCH
|
Moderate |
Decreased metabolism of Vinorelbine caused by Darunavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[46] |
Atazanavir |
DMSYRBX
|
Major |
Decreased metabolism of Vinorelbine caused by Atazanavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[26] |
Ritonavir |
DMU764S
|
Major |
Decreased metabolism of Vinorelbine caused by Ritonavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[26] |
Teriflunomide |
DMQ2FKJ
|
Major |
Additive immunosuppressive effects by the combination of Vinorelbine and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[47] |
BMS-201038 |
DMQTAGO
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by BMS-201038. |
Hyper-lipoproteinaemia [5C80]
|
[48] |
Conivaptan |
DM1V329
|
Major |
Decreased metabolism of Vinorelbine caused by Conivaptan mediated inhibition of CYP450 enzyme. |
Hypo-osmolality/hyponatraemia [5C72]
|
[26] |
Tolvaptan |
DMIWFRL
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by Tolvaptan. |
Hypo-osmolality/hyponatraemia [5C72]
|
[20] |
Berotralstat |
DMWA2DZ
|
Moderate |
Decreased metabolism of Vinorelbine caused by Berotralstat mediated inhibition of CYP450 enzyme. |
Innate/adaptive immunodeficiency [4A00]
|
[49] |
Amobarbital |
DM0GQ8N
|
Moderate |
Increased metabolism of Vinorelbine caused by Amobarbital mediated induction of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[32] |
Glycerol phenylbutyrate |
DMDGRQO
|
Moderate |
Increased metabolism of Vinorelbine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. |
Liver disease [DB90-DB9Z]
|
[24] |
Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Vinorelbine and Denosumab. |
Low bone mass disorder [FB83]
|
[50] |
Crizotinib |
DM4F29C
|
Moderate |
Decreased metabolism of Vinorelbine caused by Crizotinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[51] |
Brigatinib |
DM7W94S
|
Moderate |
Increased metabolism of Vinorelbine caused by Brigatinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[52] |
Ceritinib |
DMB920Z
|
Major |
Decreased metabolism of Vinorelbine caused by Ceritinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[26] |
PF-06463922 |
DMKM7EW
|
Moderate |
Increased metabolism of Vinorelbine caused by PF-06463922 mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[53] |
Osimertinib |
DMRJLAT
|
Moderate |
Increased metabolism of Vinorelbine caused by Osimertinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[24] |
Capmatinib |
DMYCXKL
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by Capmatinib. |
Lung cancer [2C25]
|
[54] |
Selpercatinib |
DMZR15V
|
Moderate |
Decreased metabolism of Vinorelbine caused by Selpercatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[24] |
Idelalisib |
DM602WT
|
Major |
Decreased metabolism of Vinorelbine caused by Idelalisib mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[26] |
IPI-145 |
DMWA24P
|
Moderate |
Decreased metabolism of Vinorelbine caused by IPI-145 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[55] |
Blinatumomab |
DMGECIJ
|
Moderate |
Decreased metabolism of Vinorelbine caused by Blinatumomab mediated inhibition of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[56] |
LGX818 |
DMNQXV8
|
Moderate |
Increased metabolism of Vinorelbine caused by LGX818 mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[57] |
Dabrafenib |
DMX6OE3
|
Moderate |
Increased metabolism of Vinorelbine caused by Dabrafenib mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[24] |
Lasmiditan |
DMXLVDT
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by Lasmiditan. |
Migraine [8A80]
|
[58] |
Exjade |
DMHPRWG
|
Moderate |
Decreased metabolism of Vinorelbine caused by Exjade mediated inhibition of CYP450 enzyme. |
Mineral absorption/transport disorder [5C64]
|
[59] |
Thalidomide |
DM70BU5
|
Major |
Additive thrombogenic effects by the combination of Vinorelbine and Thalidomide. |
Multiple myeloma [2A83]
|
[60] |
Tecfidera |
DM2OVDT
|
Moderate |
Additive immunosuppressive effects by the combination of Vinorelbine and Tecfidera. |
Multiple sclerosis [8A40]
|
[61] |
Siponimod |
DM2R86O
|
Major |
Additive immunosuppressive effects by the combination of Vinorelbine and Siponimod. |
Multiple sclerosis [8A40]
|
[20] |
Fingolimod |
DM5JVAN
|
Major |
Additive immunosuppressive effects by the combination of Vinorelbine and Fingolimod. |
Multiple sclerosis [8A40]
|
[62] |
Ocrelizumab |
DMEZ2KH
|
Moderate |
Additive immunosuppressive effects by the combination of Vinorelbine and Ocrelizumab. |
Multiple sclerosis [8A40]
|
[63] |
Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Vinorelbine and Ozanimod. |
Multiple sclerosis [8A40]
|
[24] |
Rifabutin |
DM1YBHK
|
Moderate |
Accelerated clearance of Vinorelbine due to the transporter induction by Rifabutin. |
Mycobacterium infection [1B10-1B21]
|
[32] |
Fedratinib |
DM4ZBK6
|
Moderate |
Decreased metabolism of Vinorelbine caused by Fedratinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[24] |
Nilotinib |
DM7HXWT
|
Moderate |
Decreased metabolism of Vinorelbine caused by Nilotinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[64] |
Omacetaxine mepesuccinate |
DMPU2WX
|
Moderate |
Additive myelosuppressive effects by the combination of Vinorelbine and Omacetaxine mepesuccinate. |
Myeloproliferative neoplasm [2A20]
|
[65] |
Modafinil |
DMYILBE
|
Minor |
Increased metabolism of Vinorelbine caused by Modafinil mediated induction of CYP450 enzyme. |
Narcolepsy [7A20]
|
[21] |
Rolapitant |
DM8XP26
|
Moderate |
Decreased clearance of Vinorelbine due to the transporter inhibition by Rolapitant. |
Nausea/vomiting [MD90]
|
[66] |
Rucaparib |
DM9PVX8
|
Moderate |
Decreased metabolism of Vinorelbine caused by Rucaparib mediated inhibition of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[67] |
Abametapir |
DM2RX0I
|
Moderate |
Decreased metabolism of Vinorelbine caused by Abametapir mediated inhibition of CYP450 enzyme. |
Pediculosis [1G00]
|
[68] |
Lefamulin |
DME6G97
|
Moderate |
Decreased metabolism of Vinorelbine caused by Lefamulin mediated inhibition of CYP450 enzyme. |
Pneumonia [CA40]
|
[69] |
Lonafarnib |
DMGM2Z6
|
Major |
Decreased metabolism of Vinorelbine caused by Lonafarnib mediated inhibition of CYP450 enzyme. |
Premature ageing appearance [LD2B]
|
[26] |
Enzalutamide |
DMGL19D
|
Moderate |
Increased metabolism of Vinorelbine caused by Enzalutamide mediated induction of CYP450 enzyme. |
Prostate cancer [2C82]
|
[70] |
Ustekinumab |
DMHTYK3
|
Moderate |
Additive immunosuppressive effects by the combination of Vinorelbine and Ustekinumab. |
Psoriasis [EA90]
|
[24] |
Tildrakizumab |
DMLW9HG
|
Moderate |
Additive myelosuppressive effects by the combination of Vinorelbine and Tildrakizumab. |
Psoriasis [EA90]
|
[24] |
Risankizumab |
DMM32GT
|
Moderate |
Additive myelosuppressive effects by the combination of Vinorelbine and Risankizumab. |
Psoriasis [EA90]
|
[24] |
Ixekizumab |
DMXW92T
|
Moderate |
Additive myelosuppressive effects by the combination of Vinorelbine and Ixekizumab. |
Psoriasis [EA90]
|
[24] |
Bosentan |
DMIOGBU
|
Moderate |
Increased metabolism of Vinorelbine caused by Bosentan mediated induction of CYP450 enzyme. |
Pulmonary hypertension [BB01]
|
[71] |
Temsirolimus |
DMS104F
|
Moderate |
Increased plasma concentrations of Vinorelbine and Temsirolimus due to competitive inhibition of the same metabolic pathway. |
Renal cell carcinoma [2C90]
|
[72] |
Gatifloxacin |
DMSL679
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Gatifloxacin. |
Respiratory infection [CA07-CA4Z]
|
[27] |
Tocilizumab |
DM7J6OR
|
Moderate |
Additive immunosuppressive effects by the combination of Vinorelbine and Tocilizumab. |
Rheumatoid arthritis [FA20]
|
[24] |
Canakinumab |
DM8HLO5
|
Moderate |
Additive myelosuppressive effects by the combination of Vinorelbine and Canakinumab. |
Rheumatoid arthritis [FA20]
|
[24] |
Rilonacept |
DMGLUQS
|
Moderate |
Additive immunosuppressive effects by the combination of Vinorelbine and Rilonacept. |
Rheumatoid arthritis [FA20]
|
[24] |
Golimumab |
DMHZV7X
|
Major |
Additive immunosuppressive effects by the combination of Vinorelbine and Golimumab. |
Rheumatoid arthritis [FA20]
|
[73] |
Dexamethasone |
DMMWZET
|
Moderate |
Increased metabolism of Vinorelbine caused by Dexamethasone mediated induction of CYP450 enzyme. |
Rheumatoid arthritis [FA20]
|
[32] |
Sarilumab |
DMOGNXY
|
Moderate |
Additive immunosuppressive effects by the combination of Vinorelbine and Sarilumab. |
Rheumatoid arthritis [FA20]
|
[24] |
Leflunomide |
DMR8ONJ
|
Major |
Additive myelosuppressive effects by the combination of Vinorelbine and Leflunomide. |
Rheumatoid arthritis [FA20]
|
[47] |
Fentanyl |
DM8WAHT
|
Moderate |
Decreased metabolism of Vinorelbine caused by Fentanyl mediated inhibition of CYP450 enzyme. |
Sensation disturbance [MB40]
|
[74] |
Anthrax vaccine |
DM9GSWY
|
Moderate |
Antagonize the effect of Vinorelbine when combined with Anthrax vaccine. |
Sepsis [1G40-1G41]
|
[75] |
Voxelotor |
DMCS6M5
|
Moderate |
Decreased metabolism of Vinorelbine caused by Voxelotor mediated inhibition of CYP450 enzyme. |
Sickle-cell disorder [3A51]
|
[76] |
Telotristat ethyl |
DMDIYFZ
|
Moderate |
Increased metabolism of Vinorelbine caused by Telotristat ethyl mediated induction of CYP450 enzyme. |
Small intestine developmental anomaly [DA90]
|
[24] |
Pitolisant |
DM8RFNJ
|
Moderate |
Increased metabolism of Vinorelbine caused by Pitolisant mediated induction of CYP450 enzyme. |
Somnolence [MG42]
|
[24] |
Fostamatinib |
DM6AUHV
|
Moderate |
Decreased metabolism of Vinorelbine caused by Fostamatinib mediated inhibition of CYP450 enzyme. |
Thrombocytopenia [3B64]
|
[77] |
Brilinta |
DMBR01X
|
Moderate |
Decreased metabolism of Vinorelbine caused by Brilinta mediated inhibition of CYP450 enzyme. |
Thrombosis [DB61-GB90]
|
[24] |
Sirolimus |
DMGW1ID
|
Moderate |
Increased plasma concentrations of Vinorelbine and Sirolimus due to competitive inhibition of the same metabolic pathway. |
Transplant rejection [NE84]
|
[72] |
Azathioprine |
DMMZSXQ
|
Moderate |
Additive myelosuppressive effects by the combination of Vinorelbine and Azathioprine. |
Transplant rejection [NE84]
|
[20] |
Tacrolimus |
DMZ7XNQ
|
Moderate |
Increased plasma concentrations of Vinorelbine and Tacrolimus due to competitive inhibition of the same metabolic pathway. |
Transplant rejection [NE84]
|
[72] |
Cinoxacin |
DM4EWNS
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Cinoxacin. |
Urinary tract infection [GC08]
|
[27] |
Nalidixic acid |
DMRM0JV
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Nalidixic acid. |
Urinary tract infection [GC08]
|
[27] |
Enoxacin |
DMYTE6L
|
Minor |
Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Enoxacin. |
Urinary tract infection [GC08]
|
[27] |
Ganciclovir |
DM1MBYQ
|
Moderate |
Additive myelosuppressive effects by the combination of Vinorelbine and Ganciclovir. |
Virus infection [1A24-1D9Z]
|
[20] |
Valganciclovir |
DMS2IUH
|
Moderate |
Additive myelosuppressive effects by the combination of Vinorelbine and Valganciclovir. |
Virus infection [1A24-1D9Z]
|
[20] |
----------- |
|
|
|
|
|